Efficacy of ustekinumab in refractory palmoplantar pustular psoriasis

British Journal of Dermatology

Volumn 168, Issue 4, 2013, Pages 820-824

  Morales Munera C ^a   Vilarrasa, E ^a   Puig, L ^a  

^a UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; CYCLOSPORIN A; ETANERCEPT; ETRETIN; LEFLUNOMIDE; METHOTREXATE; USTEKINUMAB;

ADULT; ARTICLE; CLINICAL ARTICLE; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; HUMAN; HYPERKERATOSIS; MALE; MONOTHERAPY; PRIORITY JOURNAL; PUSTULOSIS PALMOPLANTARIS; QUALITY OF LIFE; SKIN DEFECT; TREATMENT DURATION; TREATMENT OUTCOME;

ADMINISTRATION, CUTANEOUS; ADULT; ANTIBODIES, MONOCLONAL, HUMANIZED; CHRONIC DISEASE; DERMATOLOGIC AGENTS; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; MALE; MIDDLE AGED; PSORIASIS; TREATMENT OUTCOME;

EID: 84875451757     PISSN: 00070963     EISSN: 13652133     Source Type: Journal    
DOI: 10.1111/bjd.12150     Document Type: Article

References (23)

1. Chu DH, Van Voorhees AS, Rosenbach M,. Treatment of refractory tumor necrosis factor inhibitor-induced palmoplantar pustulosis: a report of 2 cases. Arch Dermatol 2011; 147: 1228-30.
2. Mrowietz U, van de Kerkhof PC,. Management of palmoplantar pustulosis: do we need to change? Br J Dermatol 2011; 164: 942-6.
3. Bordel-Gomez MT, Sanchez-Estella J, Martinez-Gonzalez O, Cardeñoso-Alvarez ME,. Palmoplantar psoriasis: a paradoxical adverse reaction induce by adalimumab. J Eur Acad Dermatol Venereol 2009; 23: 444-5.
4. Puig L, Morales-Múnera C, Lõpez-Ferrer A, Geli C,. Ustekinumab treatment of TNF-antagonist-induced paradoxical psoriasis flare in a patient with psoriatic arthritis: case report and review. Dermatology 2012; 225: 14-17.
5. Marsland AM, Chalmers R, Hollis S, et al. Interventions for chronic palmoplantar pustulosis. Cochrane Database Syst Rev 2006; 1: CD001433.
6. Adisen E, Gürer MA,. Therapeutic options for palmoplantar pustulosis. Clin Exp Dermatol 2010; 35: 219-22.
7. Au SC, Goldminz AM, Kim N, et al. Investigator-initiated, open-label trial of ustekinumab for the treatment of moderate to severe palmoplantar psoriasis. J Dermatolog Treat 2012. doi:10.3109/09546634.2012.672710 [Epub ahead of print].
8. de Unamuno-Bustos B, Ballester-Sanchez R, Oliver-Martínez V, Alegre de Miquel V,. Tratamiento de la pustulosis palmo-plantar con ustekinumab. Actas Dermosifiliogr 2011; 102: 833-5.
9. Gerdes S, Franke J, Domm S, Mrowietz U,. Ustekinumab in the treatment of palmoplantar pustulosis. Br J Dermatol 2010; 163: 1116-18.
10. Stinco G, Piccirillo F, Patrone P,. Treatment of palmoplantar pustular psoriasis with efalizumab: a quick response with early recurrence. Eur J Dermatol 2008; 18: 91-2.
11. Bissonnette R, Poulin Y, Bolduc C, et al. Etanercept in the treatment of palmoplantar pustulosis. J Drugs Dermatol 2008; 7: 940-6.
12. Floristan U, Feltes R, Ramírez P, et al. Recalcitrant palmoplantar pustular psoriasis treated with etanercept. Pediatr Dermatol 2011; 28: 349-50.
13. Brushan M, Buerden AD, McElhone K, et al. Oral liarozole in the treatment of palmoplantar pustular psoriasis: a randomized, double-blind, placebo-controlled study. Br J Dermatol 2001; 145: 546-53.
14. Baker H, Ryan TJ,. Generalized pustular psoriasis. A clinical and epidemiological study of 104 cases. Br J Dermatol 1968; 80: 771-93.
15. Asumalahti K, Ameen M, Suomela S, et al. Genetic analysis of PSORS1 distinguishes guttate psoriasis and palmoplantar pustulosis. J Invest Dermatol 2003; 120: 627-32.
16. Pettey AA, Balkrishnan R, Rapp SR, et al. Patients with palmoplantar psoriasis have more physical disability and discomfort than patients with other forms of psoriasis: implications for clinical practice. J Am Acad Dermatol 2003; 49: 271-5.
17. Safa G, Martin A, Darrieux L,. Exacerbation of infliximab-induced palmoplantar psoriasis under ustekinumab therapy in a patient with ankylosing spondylitis. J Clin Rheumatol 2011; 17: 385-6.
18. Bulai Livideanu C, Lahfa M, Mazareeuw-Haultier J, Paul C,. Efficacy of ustekinumab in palmoplantar psoriasis. Dermatology 2010; 221: 321-3.
19. Nuño-González A, Gõmez de la Fuente E, Vicente-Martín FJ, Lõpez-Estebaranz JL,. Psoriasis hiperqueratõsica palmoplantar con excelente respuesta a ustekinumab. Actas Dermosifiliogr 2012; 103: 169-70.
20. Martin DA, Towne JE, Kricorian G, et al. The emerging role of IL-17 in the pathogenesis of psoriasis: preclinical and clinical findings. J Invest Dermatol 2012. doi:10.1038/jid.2012.194 [Epub ahead of print].
21. Di Cesare A, Di Meglio P, Nestle FO,. The IL-23/Th17 axis in the immunopathogenesis of psoriasis. J Invest Dermatol 2009; 129: 1339-50.
22. Watanabe H, Kawaguchi M, Fujishima S, et al. Functional characterization of IL-17F as a selective neutrophil attractant in psoriasis. J Invest Dermatol 2009; 129: 650-6.
23. Yilmaz SB, Cicek N, Coskun M, et al. Serum and tissue levels of IL-17 in different clinical subtypes of psoriasis. Arch Dermatol Res 2012; 304: 465-9.